Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Seguro Surgical, Inc., a medical device development company specializing in the commercialization of surgical instrumentation, today announced that it has acquired, from The Johns Hopkins University, the global marketing rights to a novel device for use in abdominal surgery.

20 Oct 2009

Highly educated women deal less well with psychological aspects of breast cancer

Well-educated women and those who live alone are emotionally the hardest hit by breast cancer, according to the findings of a new Australian study announced during October's Breast Cancer Awareness Month.

20 Oct 2009

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Drugs made using unusual metals could form an effective treatment against colon and ovarian cancer, including cancerous cells that have developed immunity to other drugs, according to research at the University of Warwick and the University of Leeds.

19 Oct 2009

Access Pharmaceuticals' update on its European commercial launch of Mugard

ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

15 Oct 2009

New UCL cancer research centre launched in UK

A new centre is launched in London today (Wednesday), joining a select group of Cancer Research UK Centres across the UK.

14 Oct 2009

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Compugen Ltd. announced today that they have signed a collaboration agreement with Bayer Schering Pharma AG, Germany covering the further evaluation of a Compugen discovered tumor target and its splice variants.

13 Oct 2009

Sixth annual Medical Student Research Forum highlights latest findings

Members of Qatar's research and medical community recently gathered at Weill Cornell Medical College in Qatar to learn more about research conducted by the college's pre-medical and medical students.

13 Oct 2009

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

Women with a deleterious gene mutation are diagnosed with breast cancer six years earlier than relatives of the previous generation who also had the disease and/or ovarian cancer, according to new research from The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

Canary Foundation to implement biosensor technologies for early cancer detection

Canary Foundation has committed to being the first organization to implement the breakthrough in biosensor technologies in its research pipeline. The new technology promises to revolutionize the early detection cancer field.

12 Oct 2009

Ipsen and Spirogen sign new licensing agreement for development of SJG-136 anticancer agent

Ipsen and Spirogen Ltd. announced today that the parties have entered into a new agreement superseding their 2003 contractual relationship regarding the DNA minor groove binder SJG-136 (now known as SG2000).

8 Oct 2009

Cancer Genome Atlas funds study for analysis and interpretation of tumor genetic data

The Cancer Genome Atlas (TCGA) will fund an effort by scientists at The University of Texas M. D. Anderson Cancer Center to siphon buckets of meaningful information from an ocean of data about the aberrant genetics that drive human cancers.

8 Oct 2009

iMedicor to market Access Pharmaceuticals' MuGard in North America

ACCESS PHARMACEUTICALS, INC. announced today that it had signed an agreement with iMedicor for the North American commercial launch of MuGard, its FDA approved mucoadhesive oral rinse for the management of oral mucositis and stomatitis caused by radiotherapy and/or chemotherapy.

6 Oct 2009

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Quest PharmaTech Inc. ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. ("Paladin").

3 Oct 2009

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

Telik, Inc. today announced the publication of the positive results from a Phase 1-2a multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with nonsmall cell lung cancer (NSCLC) in a leading peer reviewed publication, the Journal of Thoracic Oncology, October 2009; Vol. 4, No. 10.

3 Oct 2009

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the Massachusetts General Hospital (MGH), in collaboration with Novelos, was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) to study two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury.

29 Sep 2009

Morphotek announces preliminary data from Phase II trial of farletuzumab

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

26 Sep 2009

There is no evidence to support the use of any test for ovarian cancer: NBOCC

In an Australian first, leading experts and organizations have agreed a position statement on screening for ovarian cancer, Australia's leading cause of death from gynecological malignancy.

23 Sep 2009

Osteoporosis a growing concern in Asia

A new audit report issued by the International Osteoporosis Foundation (IOF) today shows that osteoporosis is a serious and growing problem throughout Asia.

22 Sep 2009

Gene variant shows a strong gender bias for cancer predisposition

Cancer predisposition resulting from the presence of a specific gene variant shows a strong gender bias, researchers at the University of Cincinnati (UC) have demonstrated.

22 Sep 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” in OSI’s reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.

18 Sep 2009

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Seguro Surgical obtains global marketing rights to use a novel abdominal surgery device

Highly educated women deal less well with psychological aspects of breast cancer

Ruthenium and Osmium compounds show high levels of activity against ovarian cancer

Access Pharmaceuticals' update on its European commercial launch of Mugard

New UCL cancer research centre launched in UK

Compugen, Bayer Schering Pharma sign collaboration agreement for tumor research

Sixth annual Medical Student Research Forum highlights latest findings

Women with deleterious gene mutation diagnosed with breast cancer earlier than their previous generation

Canary Foundation to implement biosensor technologies for early cancer detection

Ipsen and Spirogen sign new licensing agreement for development of SJG-136 anticancer agent

Cancer Genome Atlas funds study for analysis and interpretation of tumor genetic data

iMedicor to market Access Pharmaceuticals' MuGard in North America

Quest PharmaTech acquires immunotherapeutic antibody products from Paladin Labs

Telik's announces positive results from Phase 1-2a TELCYTA-carboplatin-paclitaxel combination study

NIH awards Novelos and MGH $1M grant for the study of compounds for radiation-induced lung injury

Morphotek announces preliminary data from Phase II trial of farletuzumab

There is no evidence to support the use of any test for ovarian cancer: NBOCC

Osteoporosis a growing concern in Asia

Gene variant shows a strong gender bias for cancer predisposition

Notice of Allowance issued by PTO for OSI's EGFR drug

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Ovarian Cancer News and Research

Latest Ovarian Cancer News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in